Extracellular vesicles: biology and emerging therapeutic opportunities

Nature Reviews Drug Discovery, Journal Year: 2013, Volume and Issue: 12(5), P. 347 - 357

Published: April 15, 2013

Language: Английский

---

Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials

Biochimica et Biophysica Acta (BBA) - General Subjects, Journal Year: 2012, Volume and Issue: 1820(7), P. 940 - 948

Published: April 1, 2012

Language: Английский

---

Classification, Functions, and Clinical Relevance of Extracellular Vesicles

Pharmacological Reviews, Journal Year: 2012, Volume and Issue: 64(3), P. 676 - 705

Published: June 21, 2012

Both eukaryotic and prokaryotic cells release small, phospholipid-enclosed vesicles into their environment. Why do vesicles? Initial studies showed that are used to remove obsolete cellular molecules. Although this of is beneficial the cell, can also be a danger environment, for instance in blood, where provide surface supporting coagulation. Evidence accumulating cargo containers by exchange biomolecules as transmembrane receptors genetic information. Because bacteria communicate each other via extracellular vesicles, intercellular communication carriers seems conserved throughout evolution, therefore likely highly efficient, robust, economic manner exchanging information between cells. Furthermore, protect from accumulation waste or drugs, they contribute physiology pathology, have myriad potential clinical applications, ranging biomarkers anticancer therapy. may pass blood-brain barrier, perhaps even considered naturally occurring liposomes. Unfortunately, pathways vesicle themselves being tumors infectious diseases facilitate spreading, escape immune surveillance. In review, different types, nomenclature, functions, relevance will discussed.

Language: Английский

---

A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy

Biomaterials, Journal Year: 2013, Volume and Issue: 35(7), P. 2383 - 2390

Published: Dec. 15, 2013

Language: Английский

---

Extracellular vesicles as a next-generation drug delivery platform

Nature Nanotechnology, Journal Year: 2021, Volume and Issue: 16(7), P. 748 - 759

Published: July 1, 2021

Language: Английский

---

Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation

PLoS Biology, Journal Year: 2012, Volume and Issue: 10(12), P. e1001450 - e1001450

Published: Dec. 18, 2012

Extracellular vesicles (EVs) are membraneous released by a variety of cells into their microenvironment. Recent studies have elucidated the role EVs in intercellular communication, pathogenesis, drug, vaccine and gene-vector delivery, as possible reservoirs biomarkers. These findings generated immense interest, along with an exponential increase molecular data pertaining to EVs. Here, we describe Vesiclepedia, manually curated compendium (lipid, RNA, protein) identified different classes from more than 300 independent published over past several years. Even though databases indispensable resources for scientific community, recent shown that 50% not regularly updated. In addition, 20% database links inactive. To prevent such link decay, initiated continuous community annotation project active involvement EV researchers. The research can set gold standard sharing which could evolve primary resource field.

Language: Английский

---

Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells

Nanomedicine Nanotechnology Biology and Medicine, Journal Year: 2015, Volume and Issue: 12(3), P. 655 - 664

Published: Nov. 14, 2015

Language: Английский

---

Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper

Journal of Extracellular Vesicles, Journal Year: 2015, Volume and Issue: 4(1)

Published: Jan. 1, 2015

Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types participate in physiological pathophysiological processes. EVs mediate intercellular communication cell‐derived extracellular signalling organelles that transmit specific information from their of origin to target cells. As a result these properties, defined may serve novel tools for various therapeutic approaches, including (a) anti‐tumour therapy, (b) pathogen vaccination, (c) immune‐modulatory regenerative therapies (d) drug delivery. The translation into clinical requires the categorization EV‐based therapeutics compliance with existing regulatory frameworks. classification defines subsequent requirements manufacturing, quality control investigation, it is major importance define whether considered active components or primarily delivery vehicles. For an effective particularly safe practice, high level cooperation between researchers, clinicians competent authorities essential. In this position statement, basic scientists, members International Society Vesicles (ISEV) European Cooperation Science Technology (COST) program Union, namely Network on Microvesicles Exosomes Health Disease (ME‐HaD), summarize recent developments current knowledge therapies. Aspects safety must be pharmaceutical manufacturing application highlighted. Production processes discussed. Strategies promote future studies addressed.

Language: Английский

---

Extracellular vesicles in cancer — implications for future improvements in cancer care

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 15(10), P. 617 - 638

Published: May 23, 2018

Language: Английский

---

Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-inflammatory Drugs From the Nasal Region to the Brain

Molecular Therapy, Journal Year: 2011, Volume and Issue: 19(10), P. 1769 - 1779

Published: Sept. 13, 2011

In this study, exosomes used to encapsulate curcumin (Exo-cur) or a signal transducer and activator of transcription 3 (Stat3) inhibitor, i.e., JSI124 (Exo-JSI124) were delivered noninvasively microglia cells via an intranasal route. The results generated from three inflammation-mediated disease models, lipopolysaccharide (LPS)-induced brain inflammation model, experimental autoimmune encephalitis GL26 tumor showed that mice treated intranasally with Exo-cur Exo-JSI124 are protected LPS-induced inflammation, the progression myelin oligodendrocyte glycoprotein (MOG) peptide induced encephalomyelitis (EAE), had significantly delayed growth in model. Intranasal administration led rapid delivery exosome encapsulated drug was selectively taken up by microglial cells, subsequently apoptosis cells. Our demonstrate strategy may provide noninvasive novel therapeutic approach for treating inflammatory-related diseases.

Language: Английский

---